Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract

From 1976 to 1981, 26 patients with sarcomas of the female genital tract were treated with combination chemotherapy consisting of cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC). Twenty-three percent achieved an objective response including complete response in 11.5%. The 23% response rate was achieved in patients who had extensive prior treatment with other chemotherapeutic regimens and/or radiation therapy. Therefore, the use of CYVADIC as first-line chemotherapy for sarcomas of the female genital tract not amenable to surgery or radiation therapy may result in significantly higher response rates than the 23% in the present series.